Results 121 to 130 of about 2,622 (185)

Filgotinib in the treatment of infl ammatory bowel diseases

Gastroenterologie a hepatologie, 2023
openaire   +1 more source

Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease. [PDF]

World J Gastrointest Pharmacol Ther
Malakar S, Giri S, Jena A, Nath P.
europepmc   +1 more source

Efficacy/Effectiveness, Safety and Treatment Persistence of Filgotinib in Rheumatoid Arthritis: A Narrative Review of Clinical Trials and Real-World Evidence. [PDF]

Rheumatol Ther
Tanaka Y, Taylor PC, Ritsema JAS, Kondo A, Kaise T.   +4 more
europepmc   +1 more source

Corrigendum to "Preparation of colon-targeted pellets loaded with filgotinib/berberine hydrochloride and Their application in ulcerative colitis therapy" [International Journal of Pharmaceutics: X 2025 (10) 100415]. [PDF]

Int J Pharm X
Wang J, Kuang Z, Chen B, Yan C, Shi B, Li G.   +5 more
europepmc   +1 more source

Real-world experience with Janus kinase inhibitors in rheumatoid and psoriatic arthritis: retention and discontinuation factors in a UK six-centre cohort. [PDF]

Rheumatol Adv Pract
Nathan J, Farisogullari B, Jones N, Ayoub M, Brown J, Levy S, Brader J, Ersoy A, Israni B, Lloyd M, Latheef A, Hill D, Taylor A, Arachchige D, Chitsu H, Linklater H, Lather K, Gompels L, Elfar E, Malaiya R, Machado PM, Kiely PDW.   +21 more
europepmc   +1 more source

Janus Kinase Inhibitor Discontinuation at a UK Tertiary Centre: A Retrospective Study. [PDF]

Cureus
Bland K, Jubber A, Ganguly S, Moorthy A.
europepmc   +1 more source

Successful and Risk-Minimizing Treatment of Ulcerative Colitis by Positive Switch from JAK Inhibitors to Ustekinumab. [PDF]

Biologics
Otake H, Matsumoto S, Mashima H.
europepmc   +1 more source

Preparation of colon-targeted pellets loaded with filgotinib/berberine hydrochloride and Their application in ulcerative colitis therapy. [PDF]

Int J Pharm X
Wang J, Kuang Z, Chen B, Yan C, Shi B, Li G.   +5 more
europepmc   +1 more source

CVB-D attenuates experimental diabetic cardiomyopathy by alleviating mitochondrial dysfunction via the JAK1-STAT1 signaling axis in vivo and in vitro. [PDF]

Chin Med
Su H, Zhang CQ, An JF, Tuo YT, Chen TT, Yang L, Fu LY, Yao WB, Tao L, Xu YN, Shen XC.   +10 more
europepmc   +1 more source

Comparison of tofacitinib, baricitinib, upadacitinib and filgotinib: a 2-year observational study from FIRST registry. [PDF]

RMD Open
Sonomoto K, Nakayamada S, Sakai H, Ueno M, Tanaka H, Nagayasu A, Aritomi T, Okawara M, Nakata A, Tanaka Y.   +9 more
europepmc   +1 more source